What is Terrestrial Bio?
Terrestrial Bio Inc. is a biotechnology company dedicated to revolutionizing medication delivery through its proprietary microarray patch (MAP) platform. This innovative technology utilizes dissolvable microneedle patches to administer therapies transdermally, offering a more comfortable and convenient alternative to traditional injections. The MAP platform eliminates the need for refrigeration and facilitates self-administration of treatments outside of clinical environments, enhancing accessibility and patient compliance. The company's focus on improving drug delivery methods positions it as a key player in the evolving healthcare landscape.
How much funding has Terrestrial Bio raised?
Terrestrial Bio has raised a total of $57.3M across 1 funding round:
Private Equity
$57.3M
Private Equity (2026): $57.3M, investors not publicly disclosed
What's next for Terrestrial Bio?
The recent major strategic investment in Terrestrial Bio signals a strong validation of its MAP platform and its potential to disrupt conventional drug delivery methods. This capital infusion is expected to accelerate the company's research and development initiatives, potentially leading to expanded clinical trials and the commercialization of its innovative patches. The enterprise-level funding suggests Terrestrial Bio is poised for significant scaling, aiming to capture a substantial share of the transdermal drug delivery market and establish new standards for patient care and treatment accessibility.
See full Terrestrial Bio company page
